Gufic Biosciences Limited

rs,

139/LG/SE/MAY/2025/GBSL May 30, 2025 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 509079 To, National Stock Exchange of India Lim

3%

ospitals for Teicolife DCB. ➢ S-Pantoprazole IV—our enhanced pantoprazole formulation—has captured 3% market volume within 6 months. Upcoming: ➢ Full launch of our in-house contrast-media range to bo

17%

dia, with a pan-India presence Exceptional Growth: We've significantly boosted our market share to 17% (a 10-point gain). Expanding Reach: Our footprint is growing with new operations in key cities lik

5%

l, DD1, QF3) Highlights: Recent Launch Performance ▪ Vonobase (launched Jul '24) now represents ~5% of division sales ▪ ▪ Orthopaedic adoption nascent; targeted initiatives planned to accelerate grow

28%

spon: Captured 3% market share in cervical spondylosis within 8 months; repeat-prescription rate at 28%—well above category average. ➢ Baryl-DX: sold in paediatric & general segments, laying the found

INR 4

terest) in current quarter. The interest and depreciation absorbed in Q4 on account of Indore are INR 4 Cr each respectively ➢ In FY26, Indore will achieve EBIDTA breakeven ➢ Incremental Interest and De

INR 20

EBIDTA breakeven ➢ Incremental Interest and Depreciation on account of Indore in FY26 will be ~ INR 20crs and INR 16crs respectively ➢ 16 customer audits: all major partners booked; 65% complete, rem

INR 16

ven ➢ Incremental Interest and Depreciation on account of Indore in FY26 will be ~ INR 20crs and INR 16crs respectively ➢ 16 customer audits: all major partners booked; 65% complete, remainder schedul

65%

6 will be ~ INR 20crs and INR 16crs respectively ➢ 16 customer audits: all major partners booked; 65% complete, remainder scheduled by July ’25. ➢ 5 global regulatory inspections: pre-notified with h

30%

sfers from CMO partners initiated ➢ 15 new products under development at our R&D at Indore Post 30% utilization, fixed costs will absorb rapidly, and Indore will transition to a margin-accretive ass

80%

o “hot” tumours, improving immune cell infiltration and long-term tumour regression Demonstrated >80% clearance and abscopal (distant tumour) effects in preclinical mesothelioma models Preclinical E

93%

nical Efficacy • • Broad efficacy across eight solid tumour types in mouse models (cure rates 22–93%) Superior to standard-of-care FOLFIRINOX in pancreatic adenocarcinoma models (100% cure vs. 0%)

“6 Q4 FY25 Business Highlights Ferticare Division – Advancing Science-Driven Solutions in Assisted Reproductive Technology (ART) ➢ New Leadership, Renewed Focus Dr.”

“7 Q4 FY25 Business Highlights Aesthaderm – offering a comprehensive portfolio of high-quality, scientifically-backed injectable solutions ➢ Proven Leadership: Our division is now helmed by Mr.”

“This real-world evidence will be crucial for demonstrating the effectiveness and safety of our portfolio in the local context.”

“8 Q4 FY25 Business Highlights Aesthaderm Published Comparative Study in renowned Journal JCAS Statistical signifcance reduction in crow’s feet wrinkles by STUNNOX® was observed & found non-inferior to international innovator brand with no adverse events.”

“9 Q4 FY25 Business Highlights NeuroCare: Pioneering Therapeutic Botulinum Toxin in India Gufic's NeuroCare division is singularly focused on expanding the use of therapeutic botulinum toxin for neurological conditions in India and Nepal.”

“➢ Developed next-gen anti-arthritic oil formulation, set for pilot launch in Q1 FY26.”

“12 Q3 FY25 Business Highlights International Business ➢ ➢ ➢ ➢ ➢ Strategic Leadership Appointment: We are excited to announce the appointment of Dr.”

“The interest and depreciation absorbed in Q4 on account of Indore are INR 4 Cr each respectively ➢ In FY26, Indore will achieve EBIDTA breakeven ➢ Incremental Interest and Depreciation on account of Indore in FY26 will be ~ INR 20crs and INR 16crs respectively ➢ 16 customer audits: all major partners booked; 65% complete, remainder scheduled by July ’25.”

“With the above initiatives we aim to achieve it by FY27 Capitalized Q3 FY25 → 30% Utilization & EBIDTA Breakeven FY26 → Margin Accretive State FY27 14 Research & Development Update on R&D Update on Selvax • • • Peptides R&D: Paving the Way for In-house Critical API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader vision of internalizing the production of critical APIs.”

Highlights

2

Recent

1

Upcoming

1

In Development

1

Reproductive Health Expansion

1

Advancements

1

Recent

➢ Dual-chamber bag (DCB) successfully rolled out across major hospitals, including a breakthrough adoption at one of the top 5 corporate chain hospitals for Teicolife DCB. ➢ S-Pantoprazole IV—our enhanced pantoprazole formulation—has captured 3% market volume within 6 months.

Upcoming

➢ Full launch of our in-house contrast-media range to bolster Gufic Sparsh’s corporate image and drive incremental volume.

In Development

➢ Albumin and next-gen critical-care formulations advancing through formulation and stability stages. Next Steps ➢ Market Expansion: Entering Kerala’s hospital and institutional segment. ➢ Channel Growth: Onboarding additional distribution partners to accelerate hospital coverage and ensure timely delivery of quality products. 6 Q4 FY25 Business Highlights Ferticare Division – Advancing Science-Driven Solutions in Assisted Reproductive Technology (ART) ➢ New Leadership, Renewed Focus Dr. Rajeev Agarwal—who successfully headed and built Gynae portfolio brands at BSV in his past stint—has taken charge of our Fertility Cluster. His proven track record in IVF and gynae markets will accelerate our scientific positioning and brand equity, particularly across gonadotrophins. ➢ Strengthening Scientific Partnerships This quarter, we deepened collaborations with leading reproductive‐medicine communities to highlight our novel approach to treating recurrent implantation failure with Guficin Alpha

Highlights

Market Leadership: We've established the largest dedicated team for therapeutic botulinum toxin in India, with a pan-India presence Exceptional Growth: We've significantly boosted our market share to 17% (a 10-point gain). Expanding Reach: Our footprint is growing with new operations in key cities like Lucknow, Cochin, and Pune, and expanded state coverage including Gujarat, Punjab, J&K, and Uttarakhand. Physician Education: We're actively training specialists through hands-on programs, PG training, international speaker programs, and major conference participation, equipping them to effectively use our therapy. Robust Pipeline: Our future is strong with a pipeline including a proposed IVIg launch and advanced botulinum toxin formulations like Type E and Topical Botulinum Toxin. Strategic Wins: We're successfully building categories in new therapeutic areas and have secured significant Government Tenders, including the prestigious Army Tender, broadening patient access. 10 Q4 FY25 Busi

Highlights

Recent Launch Performance ▪ Vonobase (launched Jul '24) now represents ~5% of division sales ▪ ▪ Orthopaedic adoption nascent; targeted initiatives planned to accelerate growth Total vonoprazan market grew to 133.45 Cr in 12 months, with strong uptake among gastroenterologists and physicians Pipeline & Strategic Outlook

Reproductive Health Expansion

New infertility formulations for male and female indications Differentiated endometriosis therapy in development PCOS entry with novel berberine + MI combination ▪ ▪ ▪ ▪ ▪ Menopause therapy to reinforce prescription-led women's health focus ▪ Two-year roadmap in place to sustain momentum across high-opportunity areas 11 Q3 FY25 Business Highlights Healthcare Division – Advancing Pain Management & Ayurveda-Based Therapeutics The Healthcare division is focused on Ayurvedic and integrative therapies for musculoskeletal and joint disorders—most notably cervical spondylosis, chronic joint pain, osteoarthritis and gout—while building out adjacent specialties in wound healing (WH5 Gel) and gastro- intestinal health (Vonoprazan). This targeted portfolio aims to address high-incidence, under-served segments with differentiated, evidence- backed formulations. Demand Generation via Community Screening ➢ Organized 475 targeted screening camps for serum uric-acid and bone-health across priority dis